Beclomethasone (QVAR) vs ciclesonide (Alvesco)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
Beclomethasone (QVAR)
Marketed by Teva Pharmaceutical Industries
NCT02513160 · Phase 3 · completed
The trial randomized 425 participants across beclomethasone and placebo groups and used quadruple blinding with matched placebo devices. Its primary endpoint was the regulator-accepted asthma measure FEV1, and each prespecified beclomethasone-versus-placebo comparison was statistically significant, supporting a strong evidence grade.
Reported efficacy
Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk)) (Day 1 (baseline), Weeks 2, 4, 8, 12): Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results). (mixed)
Result source: NCT02040766
ciclesonide (Alvesco)
Marketed by Azurity Pharmaceuticals and partners
NCT00163397 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.
Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.
Reported efficacy
Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)
Result source: NCT00174720
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Beclomethasone (QVAR) | ciclesonide (Alvesco) |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00109668 | —Not posted · NCT00174720 |
| Trough FEV1, change | —Not posted · NCT00109668 | —Not posted · NCT00174720 |
| ACQ-5, change | —Not posted · NCT00109668 | —Not posted · NCT00174720 |
| OCS dose reduction | —Not posted · NCT00109668 | —Not posted · NCT00174720 |
Severe exacerbations, annualised rate
- Beclomethasone (QVAR)
- —Not posted · NCT00109668
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
Trough FEV1, change
- Beclomethasone (QVAR)
- —Not posted · NCT00109668
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
ACQ-5, change
- Beclomethasone (QVAR)
- —Not posted · NCT00109668
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
OCS dose reduction
- Beclomethasone (QVAR)
- —Not posted · NCT00109668
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Beclomethasone (QVAR): 0 of 4 rows · ciclesonide (Alvesco): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ciclesonide (Alvesco) |
|---|---|
| Dropout rate | —a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result11.8% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | —a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result5.1% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy |
| Serious AEs | 0%a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result0.8% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | a headaches/migraine 23.8% (placebo 22.7%) respiratory infections 19% (placebo 18.2%) bilateral otitis media 4.8% (placebo 0%) NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ciclesonide (Alvesco)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone (QVAR)'s landscape · ciclesonide (Alvesco)'s landscape